Tony Chen1, Shufeng Li2, Michael L Eisenberg3. 1. Stanford University School of Medicine, Stanford, CA, USA. Electronic address: chentony@stanford.edu. 2. Stanford University School of Medicine, Stanford, CA, USA. 3. Stanford University School of Medicine, Stanford, CA, USA. Electronic address: eisenberg@stanford.edu.
Abstract
BACKGROUND: Physician prescribing patterns surrounding the use of testosterone therapy (TTh) in men with a history of prostate cancer (CaP) is not well described. AIM: To characterize the demographics and usage patterns of testosterone therapy in men with a history of prostate cancer in the United States. METHODS: This was a retrospective review using Optum's De-identified Clinformatics Data Mart database. Administrative diagnosis, procedural, pharmacy, and laboratory codes were used to identify male subjects 40 years and older with prostate cancer treated with surgery or radiation between 2003 and 2018 who went on to receive TTh. Demographic and clinical factors are identified. Temporal trends in TTh usage were reported. OUTCOMES: The main outcomes were rates of testosterone prescriptions in men with treated prostate cancer and associated laboratory values such as Prostate Specific Antigen (PSA) and testosterone levels before TTh. RESULTS: 126,374 men completed treatment for CaP during the study period (42,515 surgery, 75,186 radiation, 8,673 both). Of these, 3,074 men (2.4%) received testosterone after CaP treatment. Men who received testosterone were younger, more likely to have erectile dysfunction, depressive disorder, and lower pretreatment PSA values compared to men who did not receive. Median PSA levels before TTh initiation were 0 - 0.2 depending on CaP treatment modality and median total testosterone level was <300 ng/dL. TTh began an average of 1.5 years after radical prostatectomy and 2.6 years after radiation treatment. We observed an increase in TTh after CaP from the beginning of the study period until it peaked in 2013 at 4.9%. After 2013, rates decreased annually until a plateau of approximately 1.8% of men. Approximately a third of men did not have testosterone labs checked before initiation of TTh. CLINICAL IMPLICATIONS: These findings provide insight into trends in testosterone prescriptions in men after prostate cancer treatment and may aid in clinical decision-making, as well as areas for improvement in cancer survivorship care. STRENGTHS AND LIMITATIONS: Strengths include the large sample size, length of data coverage, and real-world analysis of testosterone prescribing patterns across the United States. Limitations include the reliance on insurance claims data, the retrospective study design, and lack of additional relevant clinical variables that may impact decision making regarding TTh. CONCLUSION: National trends in testosterone prescriptions for men with treated prostate cancer suggest that many men are treated with TTh after prostate cancer therapy with patterns of indications and monitoring consistent with the general population. Chen T, Li S, Eisenberg M. Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States. J Sex Med 2021;18:1346-1353.
BACKGROUND: Physician prescribing patterns surrounding the use of testosterone therapy (TTh) in men with a history of prostate cancer (CaP) is not well described. AIM: To characterize the demographics and usage patterns of testosterone therapy in men with a history of prostate cancer in the United States. METHODS: This was a retrospective review using Optum's De-identified Clinformatics Data Mart database. Administrative diagnosis, procedural, pharmacy, and laboratory codes were used to identify male subjects 40 years and older with prostate cancer treated with surgery or radiation between 2003 and 2018 who went on to receive TTh. Demographic and clinical factors are identified. Temporal trends in TTh usage were reported. OUTCOMES: The main outcomes were rates of testosterone prescriptions in men with treated prostate cancer and associated laboratory values such as Prostate Specific Antigen (PSA) and testosterone levels before TTh. RESULTS: 126,374 men completed treatment for CaP during the study period (42,515 surgery, 75,186 radiation, 8,673 both). Of these, 3,074 men (2.4%) received testosterone after CaP treatment. Men who received testosterone were younger, more likely to have erectile dysfunction, depressive disorder, and lower pretreatment PSA values compared to men who did not receive. Median PSA levels before TTh initiation were 0 - 0.2 depending on CaP treatment modality and median total testosterone level was <300 ng/dL. TTh began an average of 1.5 years after radical prostatectomy and 2.6 years after radiation treatment. We observed an increase in TTh after CaP from the beginning of the study period until it peaked in 2013 at 4.9%. After 2013, rates decreased annually until a plateau of approximately 1.8% of men. Approximately a third of men did not have testosterone labs checked before initiation of TTh. CLINICAL IMPLICATIONS: These findings provide insight into trends in testosterone prescriptions in men after prostate cancer treatment and may aid in clinical decision-making, as well as areas for improvement in cancer survivorship care. STRENGTHS AND LIMITATIONS: Strengths include the large sample size, length of data coverage, and real-world analysis of testosterone prescribing patterns across the United States. Limitations include the reliance on insurance claims data, the retrospective study design, and lack of additional relevant clinical variables that may impact decision making regarding TTh. CONCLUSION: National trends in testosterone prescriptions for men with treated prostate cancer suggest that many men are treated with TTh after prostate cancer therapy with patterns of indications and monitoring consistent with the general population. Chen T, Li S, Eisenberg M. Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States. J Sex Med 2021;18:1346-1353.
Authors: Alan L Kaplan; Jim C Hu; Abraham Morgentaler; John P Mulhall; Claude C Schulman; Francesco Montorsi Journal: Eur Urol Date: 2015-12-21 Impact factor: 20.096
Authors: Alexander W Pastuszak; Abhinav Khanna; Niraj Badhiwala; Abraham Morgentaler; Mariam Hult; William P Conners; Michael F Sarosdy; Christopher Yang; Rafael Carrion; Larry I Lipshultz; Mohit Khera Journal: J Urol Date: 2015-05-27 Impact factor: 7.450
Authors: Mohit Khera; Ethan D Grober; Bobby Najari; John S Colen; Osama Mohamed; Dolores J Lamb; Larry I Lipshultz Journal: J Sex Med Date: 2009-01-22 Impact factor: 3.802
Authors: Ravi Kacker; Mariam Hult; Ignacio F San Francisco; William P Conners; Pablo A Rojas; William C Dewolf; Abraham Morgentaler Journal: Asian J Androl Date: 2016 Jan-Feb Impact factor: 3.285
Authors: David S Lopez; Hyunkyoung Kim; Efstathia Polychronopoulou; Shaden Taha; Konstantinos K Tsilidis; Alejandro Villasante-Tezanos; M Kristen Peek; Syed Gilani; Mohit Khera; Jacques Baillargeon; Yong-Fang Kuo; Steven Canfield Journal: Cancer Epidemiol Date: 2022-05-04 Impact factor: 2.890